statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

STAMFORD, Conn., April 02, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...

Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

PaxMedica (NASDAQ:PXMD - Get Free Report) and Cara Therapeutics (NASDAQ:CARA - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two...

Financial Comparison: Cara Therapeutics (NASDAQ:CARA) vs. PaxMedica (NASDAQ:PXMD)

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Cara Therapeutics to host conference call

Cara Therapeutics (NASDAQ:CARA  Get Free Report) was downgraded by StockNews.com from a hold rating to a sell rating in a research note issued on Wednesday.
A...

StockNews.com Downgrades Cara Therapeutics (NASDAQ:CARA) to Sell

STAMFORD, Conn., March 07, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...

Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024

Cara Therapeutics (NASDAQ:CARA  Get Free Report)s stock had its buy rating reissued by investment analysts at Needham & Company LLC in a report released on Tuesday...

Cara Therapeutics (NASDAQ:CARA) Receives "Buy" Rating from Needham & Company LLC

Cara Therapeutics (NASDAQ:CARA  Get Free Report) posted its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.59) earnings per share for the quarter, missing...

Cara Therapeutics (NASDAQ:CARA) Posts Quarterly  Earnings Results, Misses Estimates By $0.02 EPS

Cara Therapeutics price target lowered by $1 at Canaccord, here's why

CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.

Volume	169,234.00
52-Wk High	$4.67
52-Wk Low	$0.50

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.40	--	--	N/A
Q4'23	-$0.41	-$0.59	-42.74%	MISSED
Q3'23	-$0.52	-$0.52	--	EXPECTED
Q2'23	-$0.54	-$0.58	-7.74%	MISSED
Q1'23	-$0.51	-$0.49	4.55%	BEAT

CARA Cara Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals